Skip to Content
Due to a recent surge in pediatric RSV and flu, we are allowing only visitors 18 years of age and older in our general inpatient (hospital) settings at this time for the safety of our patients, in line with Illinois Department of Public Health guidance. Read More

Gynecologic Cancer Trials

Pilot Study of the Impact of Early Palliative Care on Quality of Life in Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Aims: The purpose of this study is to see if participants who see Palliative Care physicians at an earlier timepoint have a better quality of life.  
Diagnosis: Ovarian, fallopian tube or primary peritoneal cancer (cancer of the lining of the abdomen) for which you have already had treatment
Principal Investigator: Elena Moore, MD
IRB Approval Number: EH15-193
Sponsor: NorthShore
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

NRG-GY019: A Randomized Phase III, Two -Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum.
Aims: The purpose of this study is to see if the addition of letrozole used either by itself or in addition to usual chemotherapy will lower the chance of the cancer growing or spreading.
Diagnosis: Serous Ovarian Cancer
Principal Investigator: Mary Tilley Jenkins-Vogel, MD
IRB Approval Number: EH21-037
Sponsor: NRG Oncology
ontact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

NRG-GY022: Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin

Aims: The purpose of this study see how we can better calculate the dose of the chemotherapy drug, carboplatin
Diagnosis: any cancer
Investigator: Mary Tilley Jenkins-Vogel, MD
IRB Approval Number: EH21-038
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Open

AGCT-1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Aims: The purpose of this study is if active surveillance is an acceptable method of monitoring patients with germ cell tumors. If the cancer is standard risk, the trial is testing which chemotherapy is better.
Diagnosis: Germ Cell tumors
Principal Investigator: Mary Tilley Jenkins-Vogel, MD
IRB Approval Number: EH17-350
Sponsor: Children's Oncology Group
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

NRG-GY023: Randomized Phase II Trial of Triplet Therapy (a PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Duvalumab MEDI4736) and Cediranib or Standard of care Chemotehrapy in Women with Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Aims: The purpose of this study is to see which treatment option is the best.
Diagnosis: Ovarian, fallopian tube or primary peritoneal cancer (cancer of the lining of the abdomen)
Principal Investigator: Mary Tilley Jenkins-Vogel, MD
IRB Approval Number: EH21-361
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109.
Open to Enrollment: Open

NRG-GY012: A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent, or Metastatic Endometrial Cancer: A Platform Trial for Women with Recurrent or Persistent Endometrial Cancer
Aims: The purpose of this study is to see which treatment works best in treatng recurrent or metastatic endometrial cancer.
Diagnosis: Endometrial or Uterine cancer
Principal Investigator: Mary Tilley Jenkins-Vogel, MD
IRB Approval Number: EH2-030
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

NRG-GY018: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Aims: The purpose of this study is to see if the addition of pembrolizuamb to the standard of care drugs are better than standard of care drugs aloneherapy in controlling endometrial cancer.
Diagnosis: Endometrial Cancer
Principal Investigator: Mary Tilley Jenkins-Vogel, MD
IRB Approval Number: EH20-036
Sponsor: NRG Oncology
ontact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: suspended

NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Amonth BRCA1 Carriers (SOROCk)
Aims: The purpose of this study is to see if the removal of only fallopian tubes is no different than removal of the fallopian tubes and ovaries in ovarian cancer risk reduction.
Diagnosis: Ovarian, fallopian tube or primary peritoneal cancer (cancer of the lining of the abdomen)
Principal Investigator: Gustavo Rodriguez, MD
IRB Approval Number: EH20-324
Sponsor: NRG Oncology
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Open

GOG-3026: A Phase II Trial of Ribociclib (LEE011) plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Aims: The purpose of this study is to test any good and bad effects of the study drug, ribociclib when used with letrozole to treat low-grade serous carcinoma of the ovary or peritoneum
Diagnosis: Ovarian or primary peritoneal cancer (cancer of the lining of the abdomen)
Principal Investigator: Mary Tilley Jenkins-Vogel, MD
IRB Approval Number: EH18-395
Sponsor: Gynecologic Oncology Group
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Open

GOG-3059: Aravive, Inc. A Phase 3, Randomized, DoubleBlind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVBS6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer
Aims: The purpose of this study is to test any good and bad effects of the study drug, AVBS6-500 in combination with paclitaxel in patients with recurrent ovarian cancer
Diagnosis: Ovarian or primary peritoneal cancer (cancer of the lining of the abdomen)
Principal Investigator: Mary Tilley Jenkins-Vogel, MD
IRB Approval Number: EH21-140
Sponsor: Gynecologic Oncology Group
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109.
Open to Enrollment: Open